Psychotic, mood and anxiety disorders and venous thromboembolism: a systematic review and meta-analysis

Running title: **Psychiatric disorders and venous thromboembolism**

Célia Kowal¹, PharmaD, Hugo Peyre², MD, PhD, Ali Amad⁷, MD, PhD, Antoine Pelissolo^{3,4,5,6}, MD, PhD, Marion Leboyer^{3,4,5,6}, MD, PhD, Franck Schürhoff^{3,4,5,6}, MD, PhD, Baptiste Pignon^{3,4,5,6,*}, MD

¹AP-HP, Hôpitaux universitaires Henri-Mondor, Service de pharmacie, 94000 Créteil, France

²AP-HP, Hôpital universitaire Robert Debré, Service de pédopsychiatrie, 75019 Paris, France

³AP-HP, DMU IMPACT, Hôpitaux universitaires Henri-Mondor, Service de Psychiatrie, Créteil, 94000, France ;

⁴Inserm, U955, team 15, Créteil, 94000, France ;

⁵Fondation FondaMental, Créteil, 94000, France ;

⁶UPEC, Université Paris-Est, Faculté de médecine, Créteil, 94000, France.

⁷Univ. Lille, CNRS UMR 9193-PsyCHIC-SCALab, & CHU Lille, Pôle de Psychiatrie, Unité CURE, F-59000 Lille, France ; Fédération régionale de recherche en santé mentale (F2RSM) Hauts-de-France ; F-59000 Lille, France ; College London, Institute of Psychiatry, Psychology and Neuroscience, London, UK.

***Corresponding author:**

Dr. Baptiste Pignon

Hôpital Albert Chenevier, Groupe hospitaliers Henri-Mondor, CHU de Créteil, Assistance Publique-Hôpitaux de Paris (AP-HP), 40 rue de Mesly, 94 000, Créteil, France

baptistepignon@yahoo.fr

☎ : + 33 1 49 81 31 31 ; **Fax** : +33 1 49 81 30 59

ORCID: 0000-0003-0526-3136

ABSTRACT

Objective

Several studies have shown that psychiatric disorders can be associated with venous thromboembolism (VTE) risk, i.e. pulmonary embolism (PE) and/or deep vein thrombosis (DVT). In this study, we provide a systematic review and meta-analyses of the studies addressing this issue.

Methods

All studies addressing the risk of VTE phenomena (whole VTE, PE, DVT, fatal VTE) in subjects with psychotic, mood and anxiety disorders published between 1998 and 2019 were reviewed and included in the meta-analyses. Main characteristics of the studies and data concerning VTE risk were extracted. The methodological qualities of the studies were also analysed.

A random-effects meta-analysis model was used. A meta-analysis was conducted separately for each disorder, as well as separately for unadjusted and adjusted studies. Meta-analyses were repeated considering only good-quality studies. Heterogeneity was assessed.

Results

Sixteen studies were reviewed and 15 included in the meta-analyses. Psychotic and bipolar disorders were significantly associated with VTE risk (VTE, DVT, PE, fatal VTE for psychotic disorder, ORs between 1.29 and 2.20; VTE, DVT and PE for bipolar disorder, ORs between 1.22 and 2.14). Depression and anxiety disorders were associated with VTE risk only in adjusted analyses (DVT and PE for depression, ORs = 1.29; VTE and PE for anxiety disorders, ORs between 1.14 and 1.49).

Conclusions

The risk of VTE among subjects with psychiatric disorders may be explained by hypercoagulability and stasis, with both being related to, and independent of, treatment side-effects. VTE risk should be taken into consideration in the treatment of people with psychiatric disorders.

Keywords

Venous thromboembolism disease; Deep venous thrombosis; Pulmonary embolism; Psychotic disorders; Bipolar disorders; Depression.

Abbreviations

- DVT: Deep vein thrombosis;
- FGA: First-generation antipsychotics;
- HR: Hazard-ratio;
- HPA: Hypothalamic-pituitary-adrenal;
- MRR: Mortality rate ratio;
- NOS: Newcastle-Ottawa Scale ;
- PE: Pulmonary embolism;
- PRISMA: Preferred Reporting Items for Systematic reviews and Meta-Analyses;
- PTSD: Post-traumatic stress disorder;
- RR: Relative-risk;
- SGA: Second-generation antipsychotics;
- SMR: Standardized mortality ratios;
- SSRIs: Selective Serotonin Reuptake Inhibitors;
- VTE: Venous thromboembolism.

INTRODUCTION

Psychiatric disorders are associated with premature mortality. A recent cohort study in Denmark shows that the mortality rate ratio (MRR) of people with psychiatric disorders was 2.53 (95 % CI [2.52-2.54]), with variations according to the particular disorder (e.g., schizophrenia: MRR = 2.57, or mood disorders: MRR = 1.92) (1). Considering all psychiatric disorders, the causes of this excessive mortality can be external (i.e., suicide, accidents or homicide) or natural, including circulatory (i.e., cardiovascular or cerebrovascular: MRR = 2.45, 95 % CI [2.43-2.47]) and diabetes (MRR = 2.61, 95 % CI [2.53-2.69]). A longitudinal study of subjects with psychotic or bipolar disorders in London found standardized mortality ratios (SMR) of 2.65 (95 % CI [2.45-2.86]) for circulatory system causes, 3.38 (95 % CI [3.04-3.74]) for respiratory system causes, and 1.45 (95 % CI [1.32-1.60]) for cancers deaths (2).

Venous thromboembolism (VTE), i.e. pulmonary embolism (PE) and/or deep vein thrombosis (DVT), are the third most common cardiovascular disorders, after coronary artery disease and heart failure, with an overall annual incidence of between 100 and 200 per 100,000 inhabitants (3,4). VTE is associated with high mortality rates. In a Canadian longitudinal study based on general populations registers, the 30-day and 1-year fatality was 2.0 % and 9.2 %, and was higher when PE alone was considered (5).

Several studies and meta-analysis have shown that some psychotropic medications were associated with VTE phenomena, particularly concerning first- and second-generation antipsychotics (FGA: Odds-ratio (OR) = 1.74, 95 % CI [1.28-2.37], SGA: OR = 2.07, 95 % CI [1.74-2.52]) (6), or antidepressants drugs (Relative-risk (RR) = 1.27, 95 % CI [1.06-1.51]) (7). Other factors, such as low-grade inflammation, sedentary lifestyle, tobacco and substance use comorbidities, or metabolic syndrome are also associated with VTE phenomena (8–13). These various factors are frequently and differentially associated with different psychiatric disorders. Consequently, it would be interesting to gather and synthesize the different studies pertaining to the risk of VTE among patients with psychiatric disorders, independently of the risk factors.

Aims of the study

107 In the present systematic review and meta-analysis, our aim was to determine the risk of
108 whole venous thromboembolism, pulmonary embolism, deep vein thrombosis, and fatal venous
109 thromboembolism associated with different psychiatric disorders.

110

METHODS

We developed and followed a standard meta-analysis protocol previously registered (prospero registration number CRD42020136915, see Supplementary material).

Inclusion and exclusion criteria

The inclusion criteria of the different studies in this systematic review were:

- original studies;
- clinical prospective or retrospective studies;
- studies analysing the risk of VTE, PE, DVT, and/or fatal VTE among subjects/patients with psychiatric disorders in comparison to subjects/patients without psychiatric disorders (i.e., that published numbers of patients with and without VTE phenomena and with or without psychiatric disorders);
- targeted psychiatric disorders were: psychotic disorders, bipolar disorders, depression, anxiety disorders and catatonia.

In addition to these criteria, and in order to be meta-analysed, the different psychiatric disorders need to be studied by at least two studies. Consequently, a psychiatric disorder with only one study would be added in the systematic review but not included in the meta-analysis.

The exclusion criteria were:

- no control population;
- clinical psychiatric population (i.e. patients hospitalized in psychiatry settings, or subjects with psychiatric disorders) as control population;
- in vitro studies;
- no statistical comparison of VTE rates;
- case reports or case series;
- studies in populations of patients with a history of VTE disease (DVT and/or PE);
- no details on the different types of psychiatric disorders (psychiatric disorders treated as a whole, without precision), and/or no data on psychiatric disorders.

Search strategy and study selection

The PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines were applied for systematic reviews and meta-analyses. The search covered two databases: MEDLINE and EMBASE. Only English language articles published between June 1, 1998 and December 31, 2019 were included. The search terms were designed to provide maximum sensitivity in the detection of studies (see Supplementary material for the details of the search strategy). Duplicates were removed.

All articles found in the databases searched were reviewed. This was first based on title and abstract screening, and secondly on full-texts. Two researchers (CK and BP) independently carried out the selection of the studies and the extraction of data. Discrepancies were subsequently addressed and discussed with a third researcher (HP).

Systematic review

The considered outcomes were: main characteristics of the studies (including prospective vs. retrospective, source of the data, duration of follow-up), number of patients with and without each considered psychiatric disorder in groups with and without VTE phenomena (whole VTE, DVT, PE, and/or fatal VTE), main characteristics of case and controls (age, sex and available clinical characteristics), adjustment factors, and statistic rates (hazard-ratio (HR), OR, RR, and 95 % CI), and p-values.

The methodological quality of studies was conducted with the Newcastle-Ottawa Scale (NOS). This scale has been developed to assess the quality of nonrandomised studies with its design, content and ease of use directed to the incorporation of the quality assessments in the interpretation of meta-analytic results. Studies were judged on three broad dimensions: the selection of the study groups, the comparability of the groups and the ascertainment of either the exposure or outcome of interest for case-control or cohort studies respectively. To separate studies according to their quality, values were attributed to each grade of the notation (a = 1, b = 2, c = 3, and d = 4). Based on the mean score in the different studied characteristics in NOS, studies were median-spited and separated in two samples (i.e., low and good quality studies).

Meta-analyses

We used a random-effects meta-analysis model, which assumes that the observed estimates of VTE, DVT, PE and fatal VTE can vary across studies because of real differences in

each study as well as sampling variability. Analyses were conducted separately for the different psychiatric disorders. To examine the putative role of confounding factors, unadjusted and adjusted estimates were meta-analysed separately for each outcome (i.e. VTE, DVT, PE and fatal VTE) and each psychiatric disorder. We expected differences in the confounding variables taken into account in the adjusted model of the different studies. The robustness of the meta-analyses was determined by including only studies of good quality based on the NOS. Heterogeneity was assessed using the I^2 statistic, which represents the percentage of variation across studies due to heterogeneity, and ranges from 0 to 100 %; higher values indicate greater heterogeneity across studies (14). Publication bias was assessed using funnel plots. Statistical analyses were performed using the R package “meta” for unadjusted ORs, and the R package “metaphor” (ORs were log-transformed following Chen and Peace (15) methods) for ORs that were adjusted on confounding variables.

RESULTS

Studies selection

The search revealed 6,211 potential studies. After duplicates were removed, and titles and abstracts screened, 398 records were selected. These 398 full-texts were then reviewed to assess eligibility according to inclusion and exclusion criteria. Of these 398 records, 381 were excluded, leaving 17 studies in the qualitative analysis. As adjustment disorder and post-traumatic stress disorder (PTSD) were each analysed in only one article (16), they were not studied in the meta-analysis. No selected article assessed catatonia. As the study of Enga et al. (17) studied self-reported depression and loneliness without medical assessment, it was not included in the meta-analysis. Thus, 15 articles were included in the meta-analysis. See details in PRISMA diagram (**Figure 1**).

- FIGURE 1 -

Systematic review

Of the 17 studies included in the qualitative analysis, 15 studies concerned VTE (16–30), and 2 concerned fatal VTE (31,32). Sixteen were (prospective or retrospective) cohort studies, and one was a nested case-control study. The psychiatric disorders considered were depression (N = 12), schizophrenia (N = 10), anxiety disorders (N = 5), bipolar disorders (N = 4), and adjustment disorder and PTSD (N = 1). All of the studies used registers as source of data, except one that used interview to assess depression. Seven selected studies concerned post-operative risk of VTE. Six studies concerned only inpatients, whilst 10 studies involved inpatients and outpatients.

The details of the articles included in the systematic review are available in **Table 1**.

- TABLE 1 -

Meta-Analysis

Of the 15 studies included in the meta-analysis, 13 studies concerned VTE (18–30), and 2 fatal VTE (31,32). Among the 13 studies on non-fatal VTE, 6 assessed whole VTE phenomena without details on DVT and/or PE, 5 assessed DVT and PE, and 2 assessed only PE. The 15 articles included in the meta-analysis have been assessed according to NOS. Overall, 3 studies were considered as representative of the target population. The comparability of the groups and the follow-up (adequacy and period) were judged appropriate in the 15 studies. More details of the different fields assessed by NOS are available in supplementary table (*Supplementary Table 1*).

Detailed results of the different meta-analyses are shown in **Table 2**. Funnel plots of unadjusted meta-analyses of associations between VTE and psychiatric disorders are depicted in **Figure 2**. The meta-analyses of the good quality studies and the forest and funnel plots of adjusted meta-analyses are available in supplementary materials (*Supplementary Figure 1 and Table 2*). The different adjustment factors used in the adjusted analyses was available in supplementary table (*Supplementary Table 3*).

- TABLE 2 AND FIGURE 2 -

In unadjusted analyses, VTE was associated with psychotic disorders (OR = 2.20, 95 % CI [1.06-4.59]), in contrast to DVT, PE, and fatal VTE. Heterogeneity was high (above 99 %). The funnel plot was consistent with this high heterogeneity (**Figure 2**), but did not indicate any publication bias in favour of a positive association. Considering only adjusted analyses, VTE, DVT, PE, and fatal VTE were all associated with psychotic disorders (ORs between 1.29 and 2.88). In comparison with unadjusted analyses, heterogeneity was reduced ($I^2 = 21.3$ % for VTE, 79.1 % for DVT, and 47.4 % for PE). Considering only good quality studies, VTE, DVT and PE were associated with psychotic disorders in both unadjusted and adjusted analyses (ORs between 1.82 and 2.78 in unadjusted analyses, ORs between 1.49 and 2.02 in adjusted analyses). There were no good quality studies concerning fatal VTE and psychotic disorders.

In unadjusted analyses, VTE was associated with depression (OR = 1.86, 95 % CI [1.19-2.92]), in contrast to DVT, PE, and fatal VTE. Heterogeneity was high (I^2 above 99 %). As with psychotic disorders, the funnel plot shows this high heterogeneity, without indication of a publication bias. Considering only adjusted analyses, VTE, DVT and PE were associated with

depression (ORs between 1.19 and 1.29), in contrast to fatal VTE. In comparison with unadjusted analyses, heterogeneity was reduced ($I^2 = 43.6\%$ for VTE, and 92.1% for PE, only 1 study for DVT). When only good quality studies were considered, no studies were considered DVT, PE and fatal VTE, whereas VTE was found not to be associated with depression in both unadjusted and adjusted analyses.

In unadjusted analyses, no VTE phenomena were associated with anxiety disorders (OR = 0.64, 95 % CI [0.29-1.42]). Heterogeneity was high (I^2 above 99 %). The number of studies ($N = 3$) makes the funnel plot difficult to interpret. There were no studies concerning fatal VTE and anxiety disorders. Considering only adjusted analyses, VTE and PE were considered only in one study, and were found associated with anxiety disorders (ORs between 1.14 and 1.49). Considering only good quality studies, VTE and PE were also considered in only one study in both unadjusted and adjusted analyses (whilst DVT was not studied). VTE was associated with anxiety disorders only in adjusted analyses (OR = 1.14, 95 % CI [1.00-1.29]), while PE was associated in both unadjusted and adjusted analyses (ORs between 1.42 and 1.49).

In unadjusted analyses, all VTE phenomena, except fatal VTE, were associated with bipolar disorders (ORs between 1.48 and 1.59). Heterogeneity was high (above 99 %). As for anxiety disorder, the number of studies ($N = 2$) makes the funnel plot difficult to interpret. Considering only adjusted analyses, VTE and DVT were considered only in one study, with only DVT associated with bipolar disorders (OR = 2.14, 95 % CI [1.87-2.45]). PE was associated with bipolar disorders (OR = 2.06, 95 % CI [1.26-3.37]), with high level of heterogeneity ($I^2 = 93.3\%$). When considering only good quality studies, PE remained associated with bipolar disorders in both unadjusted and adjusted analyses (ORs between 1.22 and 1.29), whilst VTE was not associated with bipolar disorder in unadjusted and adjusted analyses, and DVT was not considered.

DISCUSSION

The systematic review and meta-analysis indicate significant associations between psychiatric disorders and VTE, DVT and PE risk. Among the psychiatric disorders, psychotic disorders were associated with the highest and most consistent ORs (except for the meta-analysis of unadjusted analyses on DVT and PE). Bipolar disorders were also associated with an increased risk of VTE, DVT and PE in the meta-analyses of unadjusted and adjusted studies, with the exception of the meta-analysis of adjusted studies on VTE risk. Meta-analyses of unadjusted analyses of depression and anxiety disorders did not show any significant associations, whereas meta-analyses of adjusted analyses of indicated associations of DVT and PE with depression, as well as VTE and PE for anxiety disorders.

Several mechanisms have been proposed to explain these associations. To develop VTE, pathophysiological studies assume that one or a combination of Virchow's triad – hypercoagulability, stasis of blood flow and vein wall injury – are necessary (33,34). Psychiatric disorders may be particularly associated with hypercoagulability and stasis factors.

Psychotic disorders and venous thromboembolism

Regarding psychotic disorders and schizophrenia, antipsychotics – in particular SGA – have been associated with VTE risk in several studies (6,35), although not all (36,37). As the side-effects of antipsychotics include sedation, negative symptoms and sedentary behaviour (38,39), they can increase the risk of venous stasis. Moreover, sedentary behaviour has been associated with inflammation-induced hypercoagulability (40,41), indicating that the well-known heightened level of inflammation evident in schizophrenia may interact with sedentary behaviours. Additionally, the putative hypercoagulability associated with antipsychotic use has been directly linked to enhanced platelet aggregation and to increased levels of anti-phospholipid antibodies (34,42). However, results across several studies are inconsistent in regard to antipsychotic-induced hypercoagulability, and thereby the antipsychotic-driven VTE risk among patients with psychotic disorders. In a sample of patients with schizophrenia, Halacheva et al. (43) did not find any association between antipsychotics and anti-phospholipid antibodies. In a sample of healthy volunteers, a reduced aggregability, and associated decreased

hypercoagulability, of blood samples was present after treatment with clozapine or olanzapine (44). In a study comparing the level of blood factors that are associated with coagulation and inflammation in schizophrenia patients treated chronically with antipsychotics and in their drug-naïve first-degree relatives, Carrizo et al. (40) did not find a homogeneous profile of inflammation and coagulation according to the different groups. However, these authors did find that the observed blood abnormalities were related to an elevated BMI in both patients and relatives. Moreover, Masopust et al. (45) studied the levels of activation of the coagulation factors in patients with acute psychotic disorders, who were antipsychotic naïve. Coagulation factors were higher among patients in comparison to controls, suggestive of a medication independent VTE risk in patients with acute psychotic disorders. Thus, the proposed association of antipsychotic use driving hypercoagulability is questionable. Gaertner et al. (46) estimated the incidence of VTE phenomena among 12,320 patients in psychiatric institutions. Although they found an incidence rate of VTE around 20 times higher than in the general population, they did not observe any association between psychotropic drugs and VTE risk. Overall, the role of antipsychotic use in the pathoetiology of VTE is questionable, indicating that the association between psychotic disorder and VTE may be explained at least partly by treatment-independent mechanisms. In the present systematic review, we report the results of one large population based nested case-control study (21), which found a significant association between VTE and psychotic disorders *after adjusting for antipsychotics use* (OR = 1.34, 95 % CI [1.15-1.55]). The authors proposed that the association between psychotic disorders and VTE may be explained by other factors, such as lifestyle habits, high BMI, or tobacco use (40,45,46). Negative symptoms may also be involved, as they are associated with sedentary behaviour (47), as well as hyperprolactinemia, metabolic syndrome, and physical restraint (48–50).

Another explanation, that concerns psychotic and non-psychotic disorders, may lie in risk factors and/or comorbidities shared by psychiatric disorders and VTE. For instance, psychotic, mood and anxiety disorders are associated with hypothalamic-pituitary-adrenal (HPA) axis dysregulation and related hypercortisolism (51–54), and hypercortisolism is associated with hypercoagulability (55,56). Likewise, low education and economic level, occupational status, obesity, metabolic syndrome, smoking, or alcohol use disorders have been linked to both VTE and psychiatric disorders (57–64). A correlate of lower socio-economic status is residence within

areas of heightened air pollution, which is also a common risk factor for both VTE and psychiatric disorders (65,66).

Mood and anxiety disorders and venous thromboembolism

The association of VTE with mood disorders parallels its association with psychotic disorders. Several studies have found significant associations between various types of antidepressants, including Selective Serotonin Reuptake Inhibitors (SSRIs), tricyclic, and other antidepressants, with VTE (7,67). However, other studies have shown no such significant associations (28,36,46,68). Of note, patients with anxiety disorders often use antidepressant and antipsychotic drugs (69,70). In an observational prospective study of patients addressed for thrombophilia investigation after a VTE episode, von Känel et al. (71) examined the role of depressive symptoms in VTE recurrence. Antidepressant use was an exclusion criterion. These authors showed that depressive symptoms were predictive of VTE recurrence, showing a “dose-effect” relationship. The results of this study, in line with the data of Enga et al. (17), support the role of medication-independent depressive symptoms in VTE risk. Again, an increase of sedentary symptoms has been proposed to underpin this association, as well as an increase in hypercoagulability induced by stress and heightened sympathetic nervous system (72,73). Such stress-driven pathophysiological changes may also underpin the association of anxiety disorders with hypercoagulability. In the study by Gaertner et al. (46) on VTE incidence in psychiatric institutions, almost one third of VTE were diagnosed during the first 48h of hospitalization, and 50 % during the first week of hospitalization, highlighting an association of VTE with the high levels of stress, dysphoria and depressive symptoms that are often evident at this time.

Other studies on psychotropic treatments of mood disorders, including benzodiazepines and mood stabilizers, showed little association with VTE risk (with the exception of one study in pregnant women, where VTE displayed a significant associations with benzodiazepine derivatives) (74,75).

Limitations

Some limitations of this study should be acknowledged. While it concerns an important topic, relative few studies have been included in this systematic review and meta-analysis. Anxiety (N = 5) and bipolar disorders (N = 4) have been poorly studied and some psychiatric

disorders, such as PTSD, catatonia, have not been studied. Moreover, as noted in the systematic review, and as confirmed by the high level of heterogeneity, inclusion criteria and clinical settings of the studies were different. Similarly, in the adjusted analyses, the heterogeneity was lower, but still high, which is consistent with different adjustment factors. Meta regressions, which could have helped to clarify the role of treatment in VTE risk could not be utilized. Other limitations arising from unavailable data, include the analysis of different adjustment factors, and psychiatric subgroups, including with and without psychotropic drug use.

Conclusion

Overall, in this systematic review and meta-analysis, the risk of VTE, DVT and PE associated with psychotic, mood, and anxiety disorders was addressed for the first time. The absolute risks of VTE of each studied psychiatric disorders, estimated based on the meta-analysis of unadjusted analyses, were as follow: psychotic disorders: OR = 2.20, 95 % CI [1.06-4.59]; depression: OR = 1.86, 95 % CI [1.19-2.92]; bipolar disorders: OR = 1.49, 95 % CI [1.23-1.80]; and anxiety disorders: OR = 0.64, 95 % CI [0.29-1.42]. Regarding details, psychotic and bipolar disorders were associated with VTE, DVT and PE risk. Depression and anxiety disorders, in adjusted analyses, show associations of DVT and PE for depression, and VTE and PE for anxiety disorders. Such results highlight the need for clinicians to be vigilant in the monitoring of VTE risk across a wide range of psychiatric disorders, which, as with other cardiovascular diseases, should have a focus that emphasizes prevention. Prevention measures, based on the use of compression stockings, hydration, behavioral activation, and sometimes prophylactic anticoagulation should be applied, especially in the case of physical restraint (76,77).

Conflict of interest: None

This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

Authors' contribution:

- Concept and design of the study: CK, HP and BP
- Systematic review: CK, HP and BP
- Analysis and interpretation of data: HP and BP
- First draft: CK and BP
- Critical review: CK, HP, AA, AP, ML, FS.

FIGURES LEGENDS

Figure1

Title: PRISMA flowchart of literature search process

Abbreviations: DVT = Deep venous thrombosis, PE = Pulmonary embolism, VTE = Venous thromboembolism events

Figure 2

Title: Funnel plots of unadjusted meta-analyses of association between psychiatric disorders and venous thromboembolism

Supplementary Figure 1

Title: Forest and funnel plots of adjusted meta-analyses of association between psychiatric disorders and venous thromboembolism

REFERENCES

1. Plana-Ripoll O, Pedersen CB, Agerbo E, Holtz Y, Erlangsen A, Canudas-Romo V, Andersen PK, Charlson FJ, Christensen MK, Erskine HE, Ferrari AJ, Iburg KM, Momen N, Mortensen PB, Nordentoft M, Santomauro DF, Scott JG, Whiteford HA, Weyerer N, McGrath JJ, Laursen TM. A comprehensive analysis of mortality-related health metrics associated with mental disorders: a nationwide, register-based cohort study. *The Lancet*. 2019;394:1827–35.
2. Das-Munshi J, Chang C-K, Dutta R, Morgan C, Nazroo J, Stewart R, Prince MJ. Ethnicity and excess mortality in severe mental illness: a cohort study. *The Lancet Psychiatry*. 2017;4:389–99.
3. Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, Greer IA, Heit JA, Hutchinson JL, Kakkar AK, Mottier D, Oger E, Samama M-M, Spannagl M, VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. *Thrombosis and Haemostasis*. 2007;98:756–64.
4. Delluc A, Tromeur C, Ven FL, Gouillou M, Paleiron N, Bressollette L, Nonent M, Salaun P-Y, Lacut K, Leroyer C, Gal GL, Couturaud F, Mottier D, Group for the E study. Current incidence of venous thromboembolism and comparison with 1998: a community-based study in Western France. *Thrombosis and Haemostasis*. 2016;116:967–74.
5. Alotaibi GS, Wu C, Senthilselvan A, McMurtry MS. Secular Trends in Incidence and Mortality of Acute Venous Thromboembolism: The AB-VTE Population-Based Study. *The American Journal of Medicine*. 2016;129:879.e19-879.e25.
6. Barbui C, Conti V, Cipriani A. Antipsychotic drug exposure and risk of venous thromboembolism: a systematic review and meta-analysis of observational studies. *Drug Safety*. 2014;37:79–90.
7. Kunutsor SK, Seidu S, Khunti K. Depression, antidepressant use, and risk of venous thromboembolism: systematic review and meta-analysis of published observational evidence. *Annals of Medicine*. 2018;50:529–37.
8. Healy D, Le Noury J, Harris M, Butt M, Linden S, Whitaker C, Zou L, Roberts AP. Mortality in schizophrenia and related psychoses: data from two cohorts, 1875-1924 and 1994-2010. *BMJ open*. 2012;2.

9. Leboyer M, Soreca I, Scott J, Frye M, Henry C, Tamouza R, Kupfer DJ. Can bipolar disorder be viewed as a multi-system inflammatory disease? *Journal of Affective Disorders*. 2012;141:1–10.
10. Saghazadeh A, Rezaei N. Inflammation as a cause of venous thromboembolism. *Critical Reviews in Oncology/Hematology*. 2016;99:272–85.
11. Song K, Rong Z, Yao Y, Shen Y, Zheng M, Jiang Q. Metabolic Syndrome and Deep Vein Thrombosis After Total Knee and Hip Arthroplasty. *The Journal of Arthroplasty*. 2016;31:1322–25.
12. Bonaldi C, Pasquereau A, Hill C, Thomas D, Moutengou E, Thanh VN, Olié V. Hospitalizations for cardiovascular diseases attributable to tobacco smoking in France in 2015. *European Journal of Preventive Cardiology*. 2019;2047487319885462.
13. Fond G, Godin O, Boyer L, Berna F, Andrianarisoa M, Coulon N, Brunel L, Bulzacka E, Aouizerate B, Capdevielle D, Chereau I, D’Amato T, Dubertret C, Dubreucq J, Faget C, Leignier S, Lançon C, Mallet J, Misdrahi D, Passerieux C, Rey R, Schandrin A, Urbach M, Vidailhet P, Llorca PM, Schürhoff F, Leboyer M, Andrianarisoa M, Aouizerate B, Bazin N, Berna F, Blanc O, Brunel L, Bulzacka E, Capdevielle D, Chereau-Boudet I, Chesnoy-Servanin G, Danion JM, D’Amato T, Deloge A, Delorme C, Denizot H, Dorey JM, Dubertret C, Dubreucq J, Faget C, Fluttaz C, Fond G, Fonteneau S, Gabayet F, Giraud-Baro E, Hardy-Bayle MC, Lacelle D, Lançon C, Laouamri H, Leboyer M, Le Gloahec T, Le Strat Y, Llorca PM, Mallet J, Metairie E, Misdrahi D, Offerlin-Meyer I, Passerieux C, Peri P, Pires S, Portalier C, Ramet L, Rey R, Roman C, Sebilleau M, Schandrin A, Schürhoff F, Tessier A, Tronche AM, Urbach M, Vaillant F, Vehier A, Vidailhet P, Vilà E, Yazbek H, Zinetti-Bertschy A, the FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group. Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia. Results from the FACE-SZ cohort. *European Archives of Psychiatry and Clinical Neuroscience*. 2019;269:985–92.
14. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ (Clinical research ed.)*. 2003;327:557–60.
15. Chen D-G (Din), Peace KE. *Applied Meta-Analysis with R*. CRC Press; 2013. 331 p.
16. Gradus JL, Farkas DK, Svensson E, Ehrenstein V, Lash TL, Milstein A, Adler N, Sørensen HT. Associations between stress disorders and cardiovascular disease events in the

471 Danish population. *BMJ Open*. 2015;5.

472 17. Enga KF, Brækkan SK, Hansen-Krone IJ, Hansen J-B. Emotional states and
473 future risk of venous thromboembolism: the Tromsø Study. *Thrombosis and Haemostasis*.
474 2012;107:485–93.

475 18. Strudsholm U, Johannessen L, Foldager L, Munk-Jørgensen P. Increased risk for
476 pulmonary embolism in patients with bipolar disorder. *Bipolar Disorders*. 2005;7:77–81.

477 19. Daumit GL, Pronovost PJ, Anthony CB, Guallar E, Steinwachs DM, Ford DE.
478 Adverse events during medical and surgical hospitalizations for persons with schizophrenia.
479 *Archives of General Psychiatry*. 2006;63:267–72.

480 20. Khaykin E, Ford DE, Pronovost PJ, Dixon L, Daumit GL. National estimates of
481 adverse events during nonpsychiatric hospitalizations for persons with schizophrenia. *General*
482 *Hospital Psychiatry*. 2010;32:419–25.

483 21. Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous
484 thromboembolism: nested case-control study. *BMJ (Clinical research ed.)*. 2010;341:c4245.

485 22. Menendez ME, Neuhaus V, Bot AGJ, Vrahas MS, Ring D. Do Psychiatric
486 Comorbidities Influence Inpatient Death, Adverse Events, and Discharge After Lower Extremity
487 Fractures? *Clinical Orthopaedics and Related Research*. 2013;471:3336–48.

488 23. Menendez ME, Neuhaus V, Bot AGJ, Ring D, Cha TD. Psychiatric disorders and
489 major spine surgery: epidemiology and perioperative outcomes. *Spine*. 2014;39:E111–122.

490 24. Stundner O, Kirksey M, Chiu YL, Mazumdar M, Poultsides L, Gerner P,
491 Memtsoudis SG. Demographics and perioperative outcome in patients with depression and
492 anxiety undergoing total joint arthroplasty: a population-based study. *Psychosomatics*.
493 2013;54:149–57.

494 25. Browne JA, Sandberg BF, D’Apuzzo MR, Novicoff WM. Depression is
495 associated with early postoperative outcomes following total joint arthroplasty: a nationwide
496 database study. *The Journal of Arthroplasty*. 2014;29:481–83.

497 26. Buller LT, Best MJ, Klika AK, Barsoum WK. The influence of psychiatric
498 comorbidity on perioperative outcomes following primary total hip and knee arthroplasty; a 17-
499 year analysis of the National Hospital Discharge Survey database. *The Journal of Arthroplasty*.
500 2015;30:165–70.

501 27. Hsu W-Y, Lane H-Y, Lin C-L, Kao C-H. A population-based cohort study on

deep vein thrombosis and pulmonary embolism among schizophrenia patients. *Schizophrenia Research*. 2015;162:248–52.

28. Lee CW-S, Liao C-H, Lin C-L, Liang J-A, Sung F-C, Kao C-H. Depression and risk of venous thromboembolism: a population-based retrospective cohort study. *Psychosomatic Medicine*. 2015;77:591–98.

29. Klement MR, Bala A, Blizzard DJ, Wellman SS, Bolognesi MP, Seyler TM. Should We Think Twice About Psychiatric Disease in Total Hip Arthroplasty? *The Journal of Arthroplasty*. 2016;31:221–26.

30. Drinane JJ, Pham T-H, Schalet G, Rezak K. Depression is associated with worse outcomes among women undergoing breast reconstruction following mastectomy. *Journal of Plastic, Reconstructive & Aesthetic Surgery*. 2019;72:1292–98.

31. Søgaaard M, Skjøth F, Kjældgaard JN, Larsen TB, Hjortshøj SP, Riahi S. Atrial fibrillation in patients with severe mental disorders and the risk of stroke, fatal thromboembolic events and bleeding: a nationwide cohort study. *BMJ open*. 2017;7:e018209.

32. Sundbøll J, Schmidt M, Adelborg K, Pedersen L, Bøtker HE, Videbech P, Sørensen HT. Impact of pre-admission depression on mortality following myocardial infarction. *The British Journal of Psychiatry: The Journal of Mental Science*. 2017;210:356–61.

33. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. *Lancet*. 2012;379:1835–46.

34. Jönsson AK, Schill J, Olsson H, Spigset O, Hägg S. Venous Thromboembolism During Treatment with Antipsychotics: A Review of Current Evidence. *CNS Drugs*. 2018;32:47–64.

35. Zhang R, Dong L, Shao F, Tan X, Ying K. Antipsychotics and venous thromboembolism risk: a meta-analysis. *Pharmacopsychiatry*. 2011;44:183–88.

36. Ray JG, Mamdani MM, Yeo EL. Antipsychotic and Antidepressant Drug Use in the Elderly and the Risk of Venous Thromboembolism. *Thrombosis and Haemostasis*. 2002;88:205–9.

37. Ferraris A, Szmulewicz AG, Posadas-Martínez ML, Serena MA, Vazquez FJ, Angriman F. The Effect of Antipsychotic Treatment on Recurrent Venous Thromboembolic Disease: A Cohort Study. *The Journal of Clinical Psychiatry*. 2019;80.

38. Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, Samara M,

- 533 Barbu C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM.
534 Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-
535 treatments meta-analysis. *The Lancet*. 2013;382:951–62.
- 536 39. Vancampfort D, Firth J, Schuch FB, Rosenbaum S, Mugisha J, Hallgren M,
537 Probst M, Ward PB, Gaughran F, Hert MD, Carvalho AF, Stubbs B. Sedentary behavior and
538 physical activity levels in people with schizophrenia, bipolar disorder and major depressive
539 disorder: a global systematic review and meta-analysis. *World Psychiatry*. 2017;16:308–15.
- 540 40. Carrizo E, Fernández V, Quintero J, Connell L, Rodríguez Z, Mosquera M,
541 Acosta A, Baptista T. Coagulation and inflammation markers during atypical or typical
542 antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives.
543 *Schizophrenia Research*. 2008;103:83–93.
- 544 41. Stubbs B, Gardner-Sood P, Smith S, Ismail K, Greenwood K, Farmer R,
545 Gaughran F. Sedentary behaviour is associated with elevated C-reactive protein levels in people
546 with psychosis. *Schizophrenia Research*. 2015;168:461–64.
- 547 42. Shen H, Li R, Xiao H, Zhou Q, Cui Q, Chen J. Higher serum clozapine level is
548 associated with increased antiphospholipid antibodies in schizophrenia patients. *Journal of*
549 *Psychiatric Research*. 2009;43:615–19.
- 550 43. Halacheva K, Dimova S, Tolev T, Dimov D, Nikolova M. Elevated
551 anticardiolipin antibodies in schizophrenic patients before and during neuroleptic medication.
552 *Psychiatry Research*. 2009;169:51–55.
- 553 44. Dietrich-Muszalska A, Rabe-Jablonska J, Nowak P, Kontek B. The first- and
554 second-generation antipsychotic drugs affect ADP-induced platelet aggregation. *The World*
555 *Journal of Biological Psychiatry: The Official Journal of the World Federation of Societies of*
556 *Biological Psychiatry*. 2010;11:268–75.
- 557 45. Masopust J, Malý R, Andrýs C, Vališ M, Bažant J, Hosák L. Markers of
558 thrombogenesis are activated in unmedicated patients with acute psychosis: a matched case
559 control study. *BMC Psychiatry*. 2011;11:2.
- 560 46. Gaertner S, Piémont A, Faller A, Bertschy G, Hallouche N, Mirea C, Le Ray I,
561 Cordeanu E-M, Stephan D. Incidence and risk factors of venous thromboembolism: Peculiarities
562 in psychiatric institutions. *International Journal of Cardiology*. 2017;248:336–41.
- 563 47. Kluge A, Kirschner M, Hager OM, Bischof M, Habermeyer B, Seifritz E, Walther

- S, Kaiser S. Combining actigraphy, ecological momentary assessment and neuroimaging to study apathy in patients with schizophrenia. *Schizophrenia Research*. 2018;195:176–82.
48. Hem E, Steen O, Opjordsmoen S. Thrombosis associated with physical restraints. *Acta Psychiatrica Scandinavica*. 2001;103:73–76.
49. Wallaschofski H, Eigenthaler M, Kiefer M, Donné M, Hentschel B, Gertz HJ, Lohmann T. Hyperprolactinemia in Patients on Antipsychotic Drugs Causes ADP-Stimulated Platelet Activation That Might Explain the Increased Risk for Venous Thromboembolism: Pilot Study. *Journal of Clinical Psychopharmacology*. 2003;23:479.
50. Ageno W, Di Minno MND, Cihan A, Ju Jang M, Hansen J-B, Steffen LM, Vayà A, Rattazzi M, Pabinger I, Oh D, Di Minno G, Brækkan SK, Cushman M, Bonet E, Pauletto P, Squizzato A, Francesco D. Association Between the Metabolic Syndrome, Its Individual Components, and Unprovoked Venous Thromboembolism. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2014;34:2478–85.
51. Tirabassi G, Boscaro M, Arnaldi G. Harmful effects of functional hypercortisolism: a working hypothesis. *Endocrine*. 2014;46:370–86.
52. Heim C, Newport DJ, Mletzko T, Miller AH, Nemeroff CB. The link between childhood trauma and depression: Insights from HPA axis studies in humans. *Psychoneuroendocrinology*. 2008;33:693–710.
53. Cherian K, Schatzberg AF, Keller J. HPA axis in psychotic major depression and schizophrenia spectrum disorders: Cortisol, clinical symptomatology, and cognition. *Schizophrenia Research*. 2019;213:72–79.
54. Belvederi Murri M, Prestia D, Mondelli V, Pariante C, Patti S, Olivieri B, Arzani C, Masotti M, Respino M, Antonioli M, Vassallo L, Serafini G, Perna G, Pompili M, Amore M. The HPA axis in bipolar disorder: Systematic review and meta-analysis. *Psychoneuroendocrinology*. 2016;63:327–42.
55. Trementino L, Arnaldi G, Appolloni G, Daidone V, Scaroni C, Casonato A, Boscaro M. Coagulopathy in Cushing's syndrome. *Neuroendocrinology*. 2010;92 Suppl 1:55–59.
56. Świątkowska-Stodulska R, Sworczak K. Disorders of Hemostasis in Overt and Subclinical Hypercortisolism. *Experimental and Clinical Endocrinology & Diabetes*. 2013;121:588–94.
57. Lorant V, Deliège D, Eaton W, Robert A, Philippot P, Ansseau M.

595 Socioeconomic inequalities in depression: a meta-analysis. *American Journal of Epidemiology*.
596 2003;157:98–112.

597 58. Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, Correlates, Disability,
598 and Comorbidity of DSM-IV Alcohol Abuse and Dependence in the United States: Results From
599 the National Epidemiologic Survey on Alcohol and Related Conditions. *Archives of General*
600 *Psychiatry*. 2007;64:830–42.

601 59. Rosengren A, Fredén M, Hansson P-O, Wilhelmsen L, Wedel H, Eriksson H.
602 Psychosocial factors and venous thromboembolism: a long-term follow-up study of Swedish
603 men. *Journal of Thrombosis and Haemostasis*. 2008;6:558–64.

604 60. Holst AG, Jensen G, Prescott E. Risk Factors for Venous Thromboembolism.
605 *Circulation*. 2010;121:1896–1903.

606 61. Zöller B, Li X, Sundquist J, Sundquist K. Socioeconomic and occupational risk
607 factors for venous thromboembolism in Sweden: A nationwide epidemiological study.
608 *Thrombosis Research*. 2012;129:577–82.

609 62. Godin O, Henry C, Leboyer M, Azorin J-M, Aubin V, Bellivier F, Polosan M,
610 Courtet P, Gard S, Kahn J-P, Loftus J, Passerieux C, Costagliola D, Etain B. Sleep quality,
611 chronotype and metabolic syndrome components in bipolar disorders during the remission
612 period: Results from the FACE-BD cohort. *Chronobiology International*. 2017;34:1114–24.

613 63. Mallet J, Le Strat Y, Schürhoff F, Mazer N, Portalier C, Andrianarisoa M,
614 Aouizerate B, Berna F, Brunel L, Capdevielle D, Chereau I, D’Amato T, Denizot H, Dubreucq J,
615 Faget C, Gabayet F, Lançon C, Llorca PM, Misdrahi D, Rey R, Roux P, Schandrin A, Urbach M,
616 Vidailhet P, Fond G, Dubertret C, Andrianarisoa M, Aouizerate B, Bazin N, Berna F, Blanc O,
617 Brunel L, Bulzacka E, Capdevielle D, Chereau-Boudet I, Chesnoy-Servanin G, Danion JM,
618 D’Amato T, Deloge A, Delorme C, Denizot H, Dorey JM, Dubertret C, Dubreucq J, Faget C,
619 Fluttaz C, Fond G, Fonteneau S, Gabayet F, Giraud-Baro E, Lacelle D, Lançon C, Laouamri H,
620 Leboyer M, Le Gloahec T, Le Strat Y, Llorca PM, Mallet J, Metairie E, Misdrahi D, Offerlin-
621 Meyer I, Passerieux C, Peri P, Pires S, Portalier C, Ramet L, Rey R, Roman C, Schandrin A,
622 Schürhoff F, Tessier A, Tronche AM, Urbach M, Vaillant F, Vehier A, Vidailhet P, Vilà E,
623 Yazbek H, Zinetti-Bertschy A. Cigarette smoking and schizophrenia: a specific clinical and
624 therapeutic profile? Results from the FACE-Schizophrenia cohort. *Progress in Neuro-*
625 *Psychopharmacology and Biological Psychiatry*. 2017;79:332–39.

64. Callaghan RC, Veldhuizen S, Jeysingh T, Orlan C, Graham C, Kakouris G, Remington G, Gatley J. Patterns of tobacco-related mortality among individuals diagnosed with schizophrenia, bipolar disorder, or depression. *Journal of Psychiatric Research*. 2014;48:102–10.
65. Khan A, Plana-Ripoll O, Antonsen S, Brandt J, Geels C, Landecker H, Sullivan PF, Pedersen CB, Rzhetsky A. Environmental pollution is associated with increased risk of psychiatric disorders in the US and Denmark. *PLOS Biology*. 2019;17:e3000353.
66. Crous-Bou M, Harrington LB, Kabrhel C. Environmental and Genetic Risk Factors Associated with Venous Thromboembolism. *Seminars in Thrombosis and Hemostasis*. 2016;42:808–20.
67. Wu C-S, Chang C-M, Chen C-Y, Wu EC-H, Wu K-Y, Liang H-Y, Chao Y-L, Chung W-SI, Tsai H-J. Association between antidepressants and venous thromboembolism in Taiwan. *Journal of Clinical Psychopharmacology*. 2013;33:31–37.
68. Lacut K, Gal GL, Couturaud F, Cornily G, Leroyer C, Mottier D, Oger E. Association between antipsychotic drugs, antidepressant drugs and venous thromboembolism: results from the EDITH case–control study. *Fundamental & Clinical Pharmacology*. 2007;21:643–50.
69. Perna G, Alciati A, Riva A, Micieli W, Caldirola D. Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review. *Current Psychiatry Reports*. 2016;18:23.
70. Pignon B, Tezenas du Montcel C, Carton L, Pelissolo A. The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive-Compulsive Disorders. *Current Psychiatry Reports*. 2017;19:103.
71. von Känel R, Margani A, Stauber S, Meyer FA, Demarmels Biasiutti F, Vökt F, Wissmann T, Lämmle B, Lukas PS. Depressive symptoms as a novel risk factor for recurrent venous thromboembolism: a longitudinal observational study in patients referred for thrombophilia investigation. *PloS One*. 2015;10:e0125858.
72. Thrall G, Lane D, Carroll D, Lip GYH. A systematic review of the effects of acute psychological stress and physical activity on haemorrhology, coagulation, fibrinolysis and platelet reactivity: Implications for the pathogenesis of acute coronary syndromes. *Thrombosis Research*. 2007;120:819–47.
73. von Känel R. Acute mental stress and hemostasis: When physiology becomes

vascular harm. *Thrombosis Research*. 2015;135:S52–55.

74. Jensen TB, Gerds TA, Grøn R, Bretler D-M, Schmiegelow MD, Andersson C, Azimi A, Gislason G, Torp - Pedersen C, Olesen JB. Risk factors for venous thromboembolism during pregnancy. *Pharmacoepidemiology and Drug Safety*. 2013;22:1283–91.

75. Ugras M, Yakinci C. Protein C, protein S and other pro- and anticoagulant activities among epileptic children using sodium valproate. *Brain and Development*. 2006;28:549–53.

76. Ishida T, Suzuki T, Watanabe K, Sakurai H, Uchida H, Mimura M. Prophylactic use of heparin for deep vein thrombosis in restrained psychiatric patients: a chart review. *General Hospital Psychiatry*. 2014;36:690–93.

77. Tezenas du Montcel C, Kowal C, Leherle A, Kabbaj S, Frajerma A, Le Guen E, Hamdani N, Schürhoff F, Leboyer M, Pelissolo A, Pignon B. Isolement et contention mécanique dans les soins psychiatriques : modalités de prescription, prise en charge et surveillance. *La Presse Médicale*. 2018;47:349–62.